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Introduction
The ageing process represents a major challenge to current health care providers. Cardiovascular disease (CVD) accounts for approximately 56% of the total mortality in the over 65 age group and represents the single largest age-related cause of death (Brock et al, 1990 , Mills et al, 1998 .
Atherosclerosis constitutes the single most important contributor to the increasing problem of CVD. A detailed understanding of the processes that contribute to the development and progression of atherosclerosis thus has important implications for the reduction of both mortality and morbidity in the elderly.
Cellular senescence is the irreversible growth arrest of mitotic cells, triggered by telomere shortening, oxidative stress or activated oncogenes (Serrano et al 1997 , Bodnar et al, 1998 , Rai et al, 2009 ). When a cell becomes senescent, it undergoes a substantial change in phenotype which is thought to predispose tissues to disease development. Many studies have investigated the potential role of cellular senescence in the development and progression of disease, including atherosclerosis (Burton, 2009 , Erusalimsky, 2009 ). Senescence in endothelial progenitor cells (EPCs), vascular endothelial cells (VECs) and vascular smooth muscle cells (VSMCs) have all been implicated in the development and progression of atherosclerosis (Yang et al, 2008 , Minamino et al, 2008 , Matthews et al, 2006 . However, the majority the of work on cellular senescence has been carried out on fibroblasts, with limited understanding of the phenotype of many other cell types, especially those linked to age-related pathology. As such, here we reported a detailed cell kinetic characterisation of the senescence of VSMCs followed by a transcriptome profile analysis, and we report changes of particular relevance to disease progression. Data on the proliferating, senescent and apoptotic fraction at each passage accompanies the analysed microarray data. This extends earlier studies reporting gene expression studies on senescence in other cell types, including fibroblasts, epithelial cells, endothelial cells and keratocytes (Shelton et al 1999 , Chen et al 2004 and Kipling et al, 2009 . Differences in the expression profiles of senescent versus proliferating cells may provide insights into the potential role of senescent VSMCs cells in atherosclerosis.
Materials and methods

Cell culture
Human aortic smooth muscle cells were obtained from Cascade Biologics and grown in Medium 231 (Cascade Biologics) supplemented with smooth muscle growth supplement (Cascade Biologics) and penicillin (50u/L) and streptomycin (50µg/L). Cells were seeded at 5 x10 3 cells/cm 2 and subcultured every 5-10 days. Cells were cleaved using trypsin:EDTA and cell numbers determined by staining cells with trypan blue and counting live cells using a Bright line haemocytometer. For the measurement of the proliferating, senescent and apoptotic fractions of the culture at every passage, VSMCs were grown on 13mm diameter glass coverslips at identical seeding density to the parent culture. Prior to passage of parent culture, coverslips were harvested and processed as described below.
Growth kinetics of human vascular smooth muscle cells
Determination of the proliferating fraction
VSMCs grown on coverslips were washed and fixed in a 1:1 mixture of methanol:acetone for 5-10 minutes at room temperature. The fixed cells were then incubated for 1 hour at room temperature with a primary antibody raised against Ki67 (Dako M0722, mouse anti-Ki67, diluted in 1% (v/v) FCS in PBS, 1/20 dilution). The cells were then washed and incubated for a further hour in the dark at room temperature with a secondary antibody conjugated with FITC (Dako F0261, rabbit anti-mouse FITC, diluted using 1% (v/v) FCS in PBS, 1/20 dilution). Cells were washed and mounted using a DAPI based mountant (Vectorshield TM ) and viewed on a fluorescent microscope. Cycling cells show highly distinctive nuclear activity. To determine the proliferating fraction, a total of 1000 cells were counted in random fields on each of three separate coverslips and the positive fraction determined.
Determination of senescence associated β-galactosidase activity
VSMCs grown on coverslips were washed and fixed in 4% paraformaldehyde for 10 minutes at room temperature. The fixed cells were washed and then incubated overnight at 37 o C in a solution of 4-chloro-5-bromo-3-indolyl-b-Dgalactoside (X-Gal) in citric acid phosphate buffer containing 5mM potassium ferrocyanide and 5mM potassium ferricyanide (Dimri et al, 1995) . To demonstrate the presence of β-galactosidase activity, one set of coverslips were incubated in buffer at pH 4; whilst to demonstrate senescence associated β-galactosidase (SA-β-gal), the incubation buffer was changed to pH 6. The cells were washed and counterstained using hematoxylin QS (Vector Labs) and nuclear fast red (Vector Labs) and viewed using a light microscope. To determine the senescent fraction, a total of 1000 cells were counted in random fields on 3 separate coverslips and the positive fraction determined. 
Determination of apoptotic fraction
Microarray Data analysis
Expression values and Absent/Present calls were calculated using MAS 5.0 (Affymetrix, 2002) and RMA (Irizarry, 2003) (Wilson and Miller, 2005) and affy (Gautier, 2004) packages.
The U133A GeneChip carries 22,215 non-control probesets corresponding to over 13387 distinct human genes (that is, 13387 distinct Entrez Gene identifiers). Detection of differentially expressed genes was performed in three distinct separate ways. First, MAS 5.0 expression values were analysed using the Bayesian t-test approach implemented by Baldi and Long (2001) in the Cyber-t package. Second, RMA data was analysed by the Cyber-t approach. Third, RMA data was analysed using the limma package (Smyth, 2004) . In each case we applied an addition filter requiring a minimum absolute fold change of at least 2 fold. Cyber-t and limma make use of moderated t statistics, which provides for greater power at small sample sizes as in this study. Multiple testing correction was performed using the False Discovery Rate (FDR) method (Benjamini and Hochberg, 1995) common threshold of 0.5%. Enrichment analysis was performed using the Metacore analysis tool from GeneGo (Genego Inc, St Joseph, MI).
Validation of microarray data
Determination of cytokine concentration by Enzyme-Linked ImmunoSorbent Assay (ELISA)
VSMCs from early (14 CPD) and late (42 CPD) passage cultures were seeded (5000 cells/cm 2 ) into 24 well plates. Growth medium was collected from triplicate wells at 2, 4 and 6 hours and stored at -80ºC until use. Cells stimulated with bacterial LPS for the purpose of invoking a cytokine response were used as positive controls. Once the optimum protein dilutions were determined, ELISA was performed using a commercial kit in accordance with the manufactures instructions (R&D systems) on the diluted samples and known standards.
Western blot analysis
Whole-cell lysates from senescent and growing VSMCs were collected using TOTEX buffer with protease inhibitors. Protein lysates (based on equal cell number, rather than equal amounts of protein) were separated using SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane. Using optimised blocking conditions (milk powder) and antibody concentrations, the PVDF membrane(s) were placed in blocking buffer for 1 hour at room temperature on an orbital shaker. Membranes were then incubated with primary antibody in blocking buffer for a further hour at room temperature.
The membranes were washed in PBS/Tween and then incubated with the appropriate secondary antibody with blocking buffer for 1 hour at room temperature followed by washing. The membranes were then incubated with the detection solution (ECL plus, Amersham Biosciences) for 5 minutes and exposed to either film or developed using a chemiluminescence imaging system (Alpha Innotech).
Reverse transcription-polymerase chain reaction (RT-PCR)
To validate the differential expression observed by microarray analysis, semiquantitative RT-PCR was also used. RNA was extracted from early (15 CPD) and late (44 CPD) passage cultures of VSMCs according to the manufacturer's protocol (QIAGEN). This RNA (based on equal cell numbers rather than equal amounts of RNA) was used to generate and amplify cDNA. PCR products were electrophoresed on 1.5% agrose TAE gel containing ethidium bromide.
GAPDH was used as a control. Quantification of the PCR products was accomplished by the use of a fluorchem imaging system (Alpha Innotech).
Results
Characterisation of senescence in human vascular smooth muscle cells
The VSMC culture used in this study proliferated for approximately 43 CPD before ceasing to expand any further ( Figure 1A ). As shown in Figure 1B , the culture initially showed a high fraction of Ki67 positive nuclei, which declined gradually with serial passage at a rate of decline of -1.29± 0.28 % Ki67
positive cells per population doubling.
The fraction of VSMCs senescence associated β-galactosidase activity (Dimri et al., 1995) throughout the lifespan of the culture is shown in Figure   1B . Less than 10% of cells stained positive until the last ten population doublings of the culture lifespan. The fraction of apoptotic (TUNEL positive) cells remained below 0.1% for most of the culture lifespan, but increased to ~1.3% in the last passage ( Figure 1B ).
Analysis of gene expression in senescent VSMCs
RNA samples were prepared from three independent replicates of early (14 CPD) and late (39-42 CPD) passage VSMC cultures and used for Affymetrix
GeneChip expression analysis to compare the transcriptome profile of proliferating and senescent VSMCs.
Three different analytical methods were used to identify genes that were differentially regulated between early and late passage VSMCs. In each case a p-value threshold was selected at which < 0.5% of the resultant probeset list would be expected to be false positives. In addition, we also required a minimum effect size of at least 2-fold differential regulation. A total of 327 probesets were called as differentially expressed by all three methods and were chosen for further analysis; 149 are up-regulated in senescence and 178 repressed. Within the up-regulated 149 sample set, vascular disease was ranked number two in the top ten GeneGo diseases. Within the repressed 178 sample set, bone tissue neoplasms are ranked within the top ten GeneGo diseases.
Validation of microarray data
In order to validate the microarray data, Western blot, ELISA and RT-PCR was undertaken on the proinflammatory cytokines IL8 and IL1β, as well as matrix Gla protein (MGP). Although IL1β protein does not appear to be secreted by early or late passage VSMCs (data not shown), immunoblot analysis of IL1β of whole cell extracts revealed a strong signal in late passage samples, with no detectable IL1 in early passage VSMCs ( Figure 5 ). It has been reported previously that in VSMCs, IL1 is not processed into its mature 17 KDa form and thus not secreted (Schonbeck et al, 1997) . VSMCs express IL1α and IL1β as 33KDa precursor proteins, which do not contain a hydrophobic leader sequence needed for secretion. Western blot analysis of IL1β confirmed these findings and presented a band at the same size of the unprocessed form of IL1β
( Figure 5 ). This unprocessed membrane bound form of IL1 has been shown to be functionally active (Loppnow and Libby, 1992) . This gradual decline in the proliferating fraction of VSMCs is probably associated with telomere shortening, resulting in an increasing likelihood of a cell becoming senescent with each serial passage. Evidence for telomere shortening in VSMCs has been provided by Matthews et al (2006) , who also showed that telomere shortening in VSMCs was closely associated with increasing severity of atherosclerosis.
The gradual decline in the growth fraction is not mirrored by the expected gradual increase in the senescent fraction (as measured by senescence associated β-galactosidase (SA-β-Gal) staining) which instead
shows an abrupt non-linear increase ( Figure 1B) . A similar observation has been made previously using human mesothelial cells (Thomas et al. 1997 ).
This abrupt increase in the senescent fraction may be related to the indirect nature of the β-galactosidase assay technique, which measures lysosomal mass (and cell size) rather than growth state (Lee et al. 2006) . Although large cell size correlates with senescence in many cell types, it is known that not all senescent cells within a given culture are large (Mitsui et al. 1981) . Thus the SA-β-Gal assay almost certainly underestimates the number of senescent cells present in a given sample (Burton et al, 2007) . This needs to be borne in mind when the assay is used in morphometric estimates of 'senescent' cell number.
The data also demonstrated that baseline apoptosis rates do not alter significantly in VSMCs as the fraction of senescent cells within the culture increases ( Figure 1B ). This finding is in agreement with both the observations of Fenton et al (2001) on rabbit neointima in vivo and data from Clark and coworkers (Norsgaard et al. 1996) , who found no difference in apoptosis rates between senescent and growing keratinocytes. This implies that senescent VSMCs may persist in vivo long enough to be of physiological significance in the pathogenesis of vascular disease. However, it has been reported that apoptosis is a feature of advanced atherosclerosis and this could promote telomere shortening (and thus senescence) by reducing the number VSMCs capable of replication (Matthews et al, 2006) . Apoptosis in this instance is likely related to disease specific changes, such as an increase in oxidative stress, which is not normally observed during cell culture. Therefore, in addition to understanding the growth kinetics of VSMCs in vitro, it is also important to have insight into factors associated with disease, which could disrupt these kinetics in vivo.
Cellular senescence of endothelial progenitor cells (EPCs), vascular endothelial cells (VECs) and vascular smooth muscle cells (VSMCs) have all been suggested to have causal roles in the development of atherosclerosis (Yang et al, 2008 , Minamino et al, 2008 , Matthews et al, 2006 . This may be due to an impaired ability to replace damaged/lost cells due to senescent EPCs, the reduced proliferative capacity of these tissues owing to the presence of senescent cells, the altered cellular phenotype of the senescent cells, the changed tissue microenvironment of the artery due to the different spectrum of proteins secreted by senescent cells, or a combination of all four.
To provide further insight into the potential mechanisms whereby senescent
VSMCs might contribute to age-related pathology, we undertook Affymetrix
GeneChip expression analysis to compare the gene expression profile of proliferating versus senescent VSMCs.
A total of 327 probesets were called as differentially expressed in senescent VSMCs by all three of the analytical methods used ( Figure S1 ) (pvalue < 0.5%, > 2 fold change): 149 are up-regulated in senescence and 178 repressed. Almost all the genes that we defined in advance from the literature as being potentially involved in vascular pathologies are found within the 327 probesets differentially regulated in senescent VSMCs (Table 1) . These differentially regulated genes have roles in inflammation, tissue remodelling or calcification and constitute less than 1.5% of all the probesets on the HG-U133A microarray. These include genes that are both up-and downregulated in senescence. In addition to this, enrichment analysis (EA) of the 149 transcripts up-regulated in senescent VSMCs, ranked "vascular disease"
at number two within the top ten GeneGo diseases. EA of the 178 repressed probesets in senescent VSMCs also provided links to calcification, with "bone tissue neoplasms" being present within the top ten GeneGo diseases. This thus suggests a strong link between the senescent transcriptome and agerelated vascular disease.
A number of key genes known to be up-regulated in atherosclerotic plaques are also highly up-regulated in senescent VSMCs. These include IL-1β (validated by Western blot analysis, Figure 5 ), IL-8 (validated by ELISA, that which we observe in vitro (Minamino et al. 2003) .
We have also demonstrated for the first time that senescent VSMCs adopt a phenotype that has the potential to predispose vascular tissue to calcification, leading to reduced elasticity and compliance. The mechanism underlying vascular calcification is currently unknown. However, a number of studies have suggested that the process of vascular calcification is similar to the mineralisation process observed in bone (Abedin et al, 2004) . (Tyson et al, 2003) . Therefore, it is not unreasonable to suggest that the observed VSMCs within calcified plaques in this instance, may in fact be senescent VSMCs.
These findings provide a strong link between the senescent phenotype of VSMCs and a potential involvement in the progression of atherosclerosis and the development of vascular calcification. The pro-inflammatory and tissue-degrading phenotype of VSMC is not a surprising one, as it appears to be a common feature of the senescent phenotype in multiple cell types, but is not necessarily a universal characteristic (Kipling et al, 2009) . It was surprising however to see senescent VSMCs adopt a pro-calcificatory phenotype. This observation suggests the need to understand cell-type specific changes which may occur during cellular senescence. An understanding of such changes would provide further insight into the relationship between cellular senescence and ageing/age-related diseases . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
